Literature DB >> 7992257

Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes.

J Malyszko1, T Urano, R Knofler, A Taminato, T Yoshimi, Y Takada, A Takada.   

Abstract

The circadian rhythms of platelet aggregation in the whole blood and platelet rich plasma-PRP and plasma serotonin were studied in healthy volunteers (n = 10) and diabetic patients (type II diabetes mellitus n = 12). Platelet aggregation in the whole blood induced by collagen (2 micrograms/ml), ADP (10 microM), arachidonic acid (0.5 mM) and epinephrine (10 microM), and in PRP induced by collagen (2 micrograms/ml), ADP (5 microM), arachidonic acid (250 microM), epinephrine (10 microM) and serotonin-5-HT (1 microM) was measured at 7:30, 11:30, 17:00, 23:00, 4:00 and 7:00. In healthy subjects collagen- and ADP-induced platelet aggregation in the whole blood was significantly lower at 23:00 and 4:00 when compared to values at 7:30. In PRP normal and diabetic platelet response was the lowest during the night. Diabetic platelets exhibited an enhanced response to 5-HT starting from 17:00 until 4:00 when compared to 7:30. 5-HT-induced platelet aggregation was found to be significantly higher throughout the study in DM patients over controls in parallel to plasma 5-HT. In healthy volunteers plasma 5-HT was higher at 17:00 when compared to baseline values, whereas in DM patients plasma 5-HT was elevated starting from 17:00 until 4:00. An enhanced response of diabetic platelets to 5-HT together with elevated plasma 5-HT levels may contribute, at least partly, to the pathogenesis of diabetic vasculopathy and 5HT2 receptor blockers may be of value in DM patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992257     DOI: 10.1016/0049-3848(94)90231-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

1.  Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes.

Authors:  Takayuki Matsumoto; Tsuneo Kobayashi; Keiko Ishida; Kumiko Taguchi; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

2.  A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy.

Authors:  T Mixcoatl-Zecuatl; C G Jolivalt
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  Molecular interactions of serotonin (5-HT) and endothelin-1 in vascular smooth muscle cells: in vitro and ex vivo analyses.

Authors:  Subha Bhaskaran; Jeremy Zaluski; Amy Banes-Berceli
Journal:  Am J Physiol Cell Physiol       Date:  2013-11-06       Impact factor: 4.249

Review 4.  Skeletal integration of energy homeostasis: Translational implications.

Authors:  Beata Lecka-Czernik; Clifford J Rosen
Journal:  Bone       Date:  2015-07-23       Impact factor: 4.398

5.  The effects of 5-hydroxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats.

Authors:  Norman E Cameron; Mary A Cotter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-13       Impact factor: 3.000

6.  Risk factors for coronary artery sclerosis in patients with diabetes.

Authors:  Akihiro Nishiyama; Chihiro Shikata; Nobuaki Kimura; Akio Imanishi; Noriyuki Hirai; Makoto Ohta; Nobuakira Takeda
Journal:  Exp Clin Cardiol       Date:  2005

7.  Loss of Serotonin Transporter Function Alters ADP-mediated Glycoprotein αIIbβ3 Activation through Dysregulation of the 5-HT2A Receptor.

Authors:  Kendra H Oliver; Matthew T Duvernay; Heidi E Hamm; Ana M D Carneiro
Journal:  J Biol Chem       Date:  2016-07-15       Impact factor: 5.157

8.  The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders.

Authors:  C Pagan; R Delorme; J Callebert; H Goubran-Botros; F Amsellem; X Drouot; C Boudebesse; K Le Dudal; N Ngo-Nguyen; H Laouamri; C Gillberg; M Leboyer; T Bourgeron; J-M Launay
Journal:  Transl Psychiatry       Date:  2014-11-11       Impact factor: 6.222

9.  Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice.

Authors:  Eun Soo Lee; Mi Young Lee; Mi-Hye Kwon; Hong Min Kim; Jeong Suk Kang; You Mi Kim; Eun Young Lee; Choon Hee Chung
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

10.  Effective treatment with combination of peripheral 5-hydroxytryptamine synthetic inhibitor and 5-hydroxytryptamine 2 receptor antagonist on glucocorticoid-induced whole-body insulin resistance with hyperglycemia.

Authors:  Shaoxin Ma; Tao Li; Keke Guo; Xin Li; Shanshan An; Shanshan Hou; Ru Chen; Bo Yang; Siyu Liu; Jihua Fu
Journal:  J Diabetes Investig       Date:  2016-05-05       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.